Updates on Immune Therapies in Type 1 Diabetes
Open Access
- 1 January 2016
- journal article
- review article
- Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology
- Vol. 12 (2), 89-95
- https://doi.org/10.17925/EE.2016.12.02.89
Abstract
Multiple clinical trials investigating the efficacy and safety of immunotherapeutic interventions in new onset type 1 diabetes (T1D) have failed to yield long term clinical benefit. Lack of efficacy has frequently been attributed to an incomplete understanding of the pathways involved in T1D and the use of single immunotherapeutic agents. Recent mechanistic studies have improved our knowledge of the complex etiopathogenesis of T1D. This in turn has provided the framework for new and ongoing clinical trials in new onset T1D patients and at-risk subjects. Focus has also shifted towards the potential benefits of synergistic combinatorial approaches, both in terms of efficacy and the potential for reduced side effects. These efforts seek to develop intervention strategies that will preserve β-cell function, and ultimately prevent and reverse clinical disease.Keywords
This publication has 40 references indexed in Scilit:
- Treg activation defect in type 1 diabetes: correction with TNFR2 agonismClinical & Translational Immunology, 2016
- Reduction in CD4 Central Memory T-Cell Subset in Costimulation Modulator Abatacept-Treated Patients With Recent-Onset Type 1 Diabetes Is Associated With Slower C-Peptide DeclineDiabetes, 2014
- Low-Dose Otelixizumab Anti-CD3 Monoclonal Antibody DEFEND-1 Study: Results of the Randomized Phase III Study in Recent-Onset Human Type 1 DiabetesDiabetes Care, 2014
- Role of B Lymphocytes in the Pathogenesis of Type 1 DiabetesCurrent Diabetes Reports, 2014
- Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation in New-Onset Type 1 Diabetes: A Multicenter AnalysisDiabetes, 2014
- B-Lymphocyte Depletion With Rituximab and β-Cell Function: Two-Year ResultsDiabetes Care, 2014
- Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trialThe Lancet Diabetes & Endocrinology, 2013
- CD4+CD45RA−FoxP3high activated regulatory T cells are functionally impaired and related to residual insulin-secreting capacity in patients with type 1 diabetesClinical and Experimental Immunology, 2013
- IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cellsThe Journal of Experimental Medicine, 2010
- Defects in IL-2R Signaling Contribute to Diminished Maintenance of FOXP3 Expression in CD4+CD25+ Regulatory T-Cells of Type 1 Diabetic SubjectsDiabetes, 2009